文献速递糖尿病肥胖与代谢综合征

MASH的药物治疗

Pharmacological treatment of MASH.
PubMed 文献 · Diabetologia · 2026-07-17

该叙述性综述评估了GLP-1受体激动剂和SGLT2抑制剂等药物对MASH的疗效及代谢获益。对于合并2型糖尿病的MASLD/MASH患者,治疗应优先包含GLP-1受体激动剂和SGLT2抑制剂,二者可改善MASLD/MASH并具有明确的心肾获益。

要点

  • 合并2型糖尿病的MASLD/MASH患者,药物治疗应优先选用GLP-1受体激动剂和SGLT2抑制剂。
  • GLP-1受体激动剂和SGLT2抑制剂可改善MASLD/MASH并提供心肾获益。
  • 除生活方式干预外,推荐对MASLD/MASH进行药物治疗。

核心结论

  • 对于合并2型糖尿病的MASLD/MASH患者,药物治疗应优先包含GLP-1受体激动剂和SGLT2抑制剂。

研究设计与样本

  • 本文为叙述性综述,评估GLP-1受体激动剂和SGLT2抑制剂等药物治疗MASLD/MASH的疗效及代谢获益。

主要发现

  • GLP-1受体激动剂和SGLT2抑制剂已被证明可改善MASLD/MASH,并提供明确的心肾获益。

关键数值与推荐

  • 对于合并2型糖尿病的MASLD/MASH患者,治疗应优先包含GLP-1受体激动剂和SGLT2抑制剂。
  • 除生活方式干预(健康低能量饮食和增加体力活动)外,推荐对MASLD/MASH进行药物治疗。

临床怎么用

  • 对合并2型糖尿病的MASLD/MASH患者,处方降糖药时应优先考虑GLP-1受体激动剂或SGLT2抑制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic dysfunction-associated steatotic liver disease (MASLD) includes a spectrum of progressive liver conditions ranging from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), advanced fibrosis and cirrhosis. Currently, MASLD is the leading cause of chronic liver disease worldwide. MASLD is strongly associated with type 2 diabetes, cardiovascular disease, chronic kidney disease and certain extrahepatic cancers. MASLD shares a common pathogenesis with cardiometabolic diseases, especially type 2 diabetes, primarily driven by unhealthy dietary habits, dysfunctional adipose tissue, insulin resistance and low-grade inflammation. Substantial heterogeneity in the pathophysiology of MASLD may influence its rate of progression, its relationship with cardiometabolic diseases and its treatment response. In addition to lifestyle interventions, including a healthy low-energy diet and increased physical activity levels, pharmacological treatment of MASLD/MASH is recommended. For individuals with type 2 diabetes and MASLD/MASH, treatment should preferably include glucagon-like peptide-1 (GLP-1) receptor agonist-based therapies and sodium-glucose cotransporter 2 (SGLT2) inhibitors, which have been shown to improve MASLD/MASH and provide established cardiorenal benefits. In this narrative review, we assess the efficacy of these pharmacotherapies and discuss other treatment approaches for MASLD/MASH, with a focus on their metabolic benefits.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Stefan N, Targher G. Pharmacological treatment of MASH. Diabetologia. 2026. PMID: 42467088. doi:10.1007/s00125-026-06796-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。